A competitive particle concentration fluorescence immunoassay (PcFIA) is described for measuring 5,1 0-dideaza- 5,6,7,8-tetrahydrofolic acid (lometrexol; Lilly) in human serum. b-Phycoerythrin-labeled lometrexol competes with free lometrexol for binding to a limiting concentration of lometrexol-specific antibodies immobilized by a second antibody to submicrometer-diameter polystyrene particles in specially designed 96-well plates. Reaction particles are washed and concentrated onto filter membranes in the wells of the plates and the fluorescence is measured at 575 nm. The method, includingsample preparation and data reduction, is automated and can be completed in <2 h. The assay has a standard curve maximum measurable concentration of 1000 zg/L and a minimum detectable concentration of 0.1 Lg/L. Analytical recovery of lometrexol in serum is quantitative at concentrations >1 ig/L. Intra-and interassay coefficientsof variation at 50 g/L in serum are 7.1% (n = 9) and 7.5% (n = 33), respectively. (8) (9) (10) . In these sandwich PCFIAs, an entire assay plate (up to 96 samples) can be completed in <20 mm.
fast reaction kinetics. An automated analyzer can be programmed to automatically add reagents, incubate, wash, filter, and perform fluorescencemeasurements on as many as 10 assay plates. Pcn& is frequently used in a two-site sandwich format for the rapid screening of monoclonal antibodies in supernates of hybridoma cultures (8) (9) (10) . In these sandwich PCFIAs, an entire assay plate (up to 96 samples) can be completed in <20 mm.
We have developed a competitive PCFIA for the rapid measurement of lometrexol in human serum. Lometrexol is covalently attached to the fluorescent protein b-phycoerythrin (BPE). The conjugate competes with free lometrexol for binding to lometrexol-specific antibodies immobilized by a secondantibody to polystyrene particles. We used a TecanTM robotic system to prepare and then transfer diluted samples to the microtiter plates. We found that although this competitive PCFIA required a 1-h incubation outside the Screen Machine, as many as 96 samples could still be assayed in <2 h. We describe the assay method and its performance characteristics, e.g., detection limit, sensitivity, impre-cision, recovery, and cross-reactivity . We also report use of the PCFIA for pharmacokinetic studies of lometrexol administered to cancer patients.
Materials and Methods

Equipment
The Pandex Screen MachineTM analyzer and non- We immunized three New Zealand White male rabbits (1.8-2.7 kg) with lometrexol-KLH according to an accelerated booster schedule. Initially, the rabbits were injected with -50 p.g of hapten (calculated from the lometrexol:KLH molar conjugation ratio) prepared in 1.0 mL of Freund's complete adjuvant.-Tween 80 double emulsions (12, 14) . At seven and 14 days after the primary immunization, the animals were boosted with --25 pg of hapten prepared in 1 Step 2 applied suction to the plate for 1.6 mm, washed with TBSA and suctioned for 1.6 mm, washed with TBSA and suctioned for 1.6 mm, and read the fluorescence using "C" and "B" filters (described below) at a x25 gain. Between Steps 1 and 2 we manually removed the plates from the Screen Machine, and incubated them for 60 mm at room temperature in a humidified chamber.
According to the procedure above, the specific rabbit antibodies, bound by goat anti-rabbit IgG coated on the submicrometer polystyrene particles, reacted with competing BPE-labeled lometrexol and unlabeled lometrexol. After the 60-min incubation, the reaction mixture was filtered and washed to remove unbound label. The specific particle-bound fluorescence of every well was measured by front-face fluorometry in a dualwavelength mode. Excitation and emission wavelengths specificfor BPE (545 nm/575 nmem,"C" filter) and the reference particle (590 nm/620 nrnem,"B" ifiter) fluorophors were used. Incorporating reference particles and calculating fluorescence ratios in the PCFIA corrected for well-to-well differences in the pipetting of assay particles (9). All precision estimates reported in this paper were determined in the presence of reference particles. Samples were assayed near or below the EC of the standard curve where maximum precision was observed. The concentration of reference particles was chosensothat the ratio of BPE fluorescenceto reference particle fluorescencewas 1:1 in that region. We performed size-exclusion chromatography on normal serum to which we added lometrexol and on samples from lometrexol-treated patients' samples to determine the molecular size of the immunoreactive components. The fractions collected were assayed for immunoreactivity by PCFIA. Lometrexol was also added to several buffers and assayed by PCFIAto ensure that the compound was not bound by buffer components such as BSA. The buffers TBST (per liter, 100 mmol of Tris, 250 rnmol of NaC1, and 2.5 mL of , PBSA (per liter, 50 mmol of sodium phosphate, 100 mmol of NaC1, 2.5 nmol of EDTA, 15 nmol of sodium azide, and 15mg of BSA), and 20% NHS/TBSA were prepared to contain lometrexol at a final concentration of 10 p.g/L, then were incubated overnight at 4#{176}C. An undiluted pre-dose patient's sample and a sample from the same patient determined by PCFIA to have a 10 pg/L concentration of lometrexol in serum were also assayed. For size-exclusion chromatography we used a Fast DesaltTMColumn HR1O/10 (Sephadex G-25 superfine gel matrix with an exclusion limit of 5000 kDa; Pharmacia, Piscataway, NJ) and a mobile phase containing, per liter, 100 mmol of Tris, 150 mmol of NaCl, and 15 nmol of sodium azide, pH 8.0, at a flow rate of 1 mL/min with a run time of 21 mm. Samples (100 p.L) were injected onto the column, and 0.7-mL fractions were collected in 12 x 75-mm polystyrene tubes. The tubes were transferred to the Tecan RSP 505, and 20-1zL aliquots of each fraction were dispensedonto Epicon plates as described. Fractions were assayed by PCFIA as described. were between ages 38 and 72 years, had a life expectancy of at least four months, and were ambulatory. No restrictions were placed on gender, and all patients met minimal criteria for hernatological conditions. Lometrexol was administered intravenously to patients at 15 mg/rn2(n = 2), 30mg/rn2 (n = 12), and 60 mg/rn2 (n = 2). Blood samples were drawn at specifiedtimes for up to 24 h after dosing. Whole blood was allowed to clot at room temperature for 10-15 mm. Serum was then obtained by centrifugation at 3000 x g for 15 mm at 4#{176}C. Serum aliquots of 1 mL were stored in 12 x 75 mm polypropylene tubes at -20 #{176}C. Before analysis by PCFLA, the serum samples were thawed, vortex-mixed, and centrifuged at 3000 x g for 15 mm at 4#{176}C to remove any insoluble cryoprecipitate. A conventional computerbased, model-independent method was used to calculate the pharmacokinetic variables of volume of distribution, the systemic clearance, and the half-life of lometrexol.
Results
Time required to reach assay equilibrium.
An incubation of at least 45 mm was necessary to achieve maximal fluorescence values (--43 000 arb. units). We incubated all assays for 60 mm to ensure that equilibrium had been achieved.
Assay performance. The standard curve for the PCFIA of lometrexol showed a broad range of detection ( Figure  2) . The assay had a maximum measurable concentration of 1000 pg/L and a minimum detectable concentration of 0.1 p.g/L. The slope of the PCFIA log-logit standard curve was 0.5, with CVs 5% for the fluorescence values over the entire range of the assay.
Intra-and interassay variability.
Intra-assay variability was assessed by adding lometrexol to normal human serum at a final concentration of 5 and 50 pg/L. Intraassay CVs for the measurements in human serum were 7.1% (n = 9) and 6.6% (n = 9) at the 5 and 50 pg/L concentrations. Interassay CVs were 11.1%, 6.6%, 7.5%, and 11.7% (n = 33 each) for lometrexol at concentrations of 1, 5, 50, and 500 p.g/L, respectively, in human serum. Analytical recovery. Lometrexol was added to normal human serum and quantified. The expected and measured concentrations of lometrexol are shown in Table 1 . The results show that lometrexol was quantitatively (CV 2.8%), and 4.5 (CV 3.6%), respectively. Because the degree of hemolysis in most patients' samples is moderate at worst, the effect of erythrocyte lysis on lometrexol quantification in patients' serum appears to be negligible.
Cross-reactivity.
We determined the specificity of the assay by measuring the cross-reactivities of the following endogenous folates: folic acid, THF, 5,6-dihydrofolic acid, N5-formyl-THF; and N5-methyl-TI{F.
The crossreactivities of the structurally related compounds N5-deaza-THF, lometrexol "isomer A," and methotrexate were also determined. Percent cross-reactivities were calculated at EDso (Table 2) 
Discussion
We evaluated PCFJA as a fast, automated immunoassay technique for measuring of the low-molecular-mass drug, lometrexol, in serum. The PCFIA provided a low detection capability, high specificity, and good precision.
During the development and validation of this method, we made two observations that are particularly relevant for serum-based PCFIA5. First, undiluted serum samples frequently clogged the 0.22-zm pore-size filter membranes of the Epicon plates, preventing filtration and resulting in erroneous fluorescence readings. We were able to overcome this problem by either prefiltering samples or diluting the serum at least fivefold with TBSA. We chose to perform dilutions, which was simpler to automate than filtration. The low-concentration detection limit of the standard curve was -=0.1 pg/L and so we were able to accurately report results for serum samples containing as little as 1 pg of lometrexol per liter. This PCFIA method will clearly provide the detection capabilities required to measure even lower concentrations of lometrexol than were observed in the serum of patients involved in this Phase I study. Lesssensitive PCFIA8 may be compromised by the necessity to pre-dilute samples for assay. Second,we discovered a trending phenomenon in this and several other competitive PCFLAs that we have developed (manuscript in preparation). The effect is a decrease (-=25%) in fluorescencefrom left to right across the Epicon assay plate, which, in competitive PCFIA5, results in anomalously high potency estimates for sampies located in the right-most portion of the plate. We determined that this effect could be eliminated by performing the incubation step outside the Screen Machine. This observation prompted us to process our plates by the two-step protocol described in Materials and Methods, which, in addition to the random sample placement, reduced positional biases to less than the intra-assay variability. Other laboratories performing PCFIAsshould be on the alert for this phenomenon.
We performed this assay by using different degrees and methods of automation. We diluted and added samples to the Epicon plates either entirely by hand, or by using the Tecan or Biomek 1000 liquid-handling systems. Our results did not reveal a significant difference in the precision of the three approaches (data not shown). However, in terms of reliability, the Tecan provided superior unattended performance, when compared with the Biomek. The Biomek required replacement of reagent trays and plates, and occasionally malfunctioned due to tip mishandling. On the other hand, the Biomek could processthe assay plates faster than the Tecan, because of greater versatility of liquid handling.
The PCFIA for lometrexol was highly specific. The polyclonal antiserum to lometrexol was partially stereospecific and distinguished the C6 epimers of lometrexol. The reactivity of the polyclonal antiserum with folate analogs suggested that binding was directed predominantly against the pteroyl moeity. We evaluated several potential sources of interference in the measurement of lometrexol in serum. A foremost concern was the presence of endogenous folates, which, because of their structural similarity with lometrexol, might crossreact with the polyclonal antiserum. Our evaluation of several commercially available folates revealed no cross-reactivities with the antiserum. Furthermore, no increase was observed in the PCFIA response for serum collected from samples containing lysed erythrocytes, which are known to release high concentrations of folates (17) . Another concern was that circulating highaffinity folate-binding proteins might bind lometrexol and result in a lower response in the PCFIA (18). The size-exclusion chromatography experiments showed that the binding of lometrexol to serum proteins is negligible in the presence of physiological concentrations of folic acid. Our results clearly showed that the lometrexol immunoreactivity measured in patients' samples was not associated with macromolecules in serum.
In conclusion, we have shown that PCFIA technology can be applied, in a competitive format, to the measurement of low concentrations of lometrexol in serum. The speed and automatability of PCF'IAs make this technology a powerful alternative to traditional immunoassay methods. provided the procedure for the N-hydroxysuccinimide-activation of the lometrexol. We also thank Patsy Swisher for her editorial assistance.
